Castration-resistant prostate cancer (CRPC) develops when prostate cancer continues to grow despite androgen deprivation therapy (ADT), which reduces testosterone to very low levels. CRPC is not a single disease but a spectrum of conditions, ranging from rising PSA with no visible spread (non-metastatic CRPC, or nmCRPC) to widespread metastatic disease (mCRPC).
The androgen receptor (AR) is the central driver of most prostate cancer growth. Even when circulating testosterone is suppressed by ADT, cancer cells can sustain AR signaling through several escape mechanisms: amplification of the AR gene (found in 20-80% of CRPC cases), mutations that make the AR respond to non-testosterone hormones, and production of splice variants like AR-V7 that are constitutively active without any hormone signal at all.
Tumors can also synthesize their own androgens from cholesterol through intratumoral androgen synthesis, bypassing the need for circulating testosterone entirely. This explains why simply lowering blood testosterone is insufficient to control many CRPCs -- the tumor becomes its own hormone factory.
Beyond AR, cancer cells can activate entirely different survival pathways to become AR-independent: growth factor signaling through IGF-1, EGF, and HER-2, the PI3K/Akt cell survival cascade, anti-apoptotic Bcl-2 proteins, and transformation into neuroendocrine prostate cancer (NEPC) -- an aggressive AR-negative subtype with very poor prognosis.
Prostate-Specific Membrane Antigen (PSMA) is a protein highly overexpressed on the surface of prostate cancer cells, making it an ideal drug delivery target. PSMA radioligand therapy attaches a radioactive particle directly to a molecule that binds PSMA, delivering lethal radiation precisely to cancer cells while sparing surrounding tissue.
177Lu-PSMA-617 (Pluvicto) received FDA and EMA approval after the landmark VISION trial showed it significantly extended overall survival in men with metastatic CRPC who had already received ARPI and taxane chemotherapy. The PSMAfore trial is currently evaluating its use earlier in the treatment sequence, before chemotherapy.
The effectiveness of PSMA-targeted therapy depends on the tumor expressing adequate PSMA levels, which is confirmed before treatment using PSMA PET/CT imaging. Approximately 5-10% of CRPCs have low or absent PSMA expression -- particularly those with neuroendocrine differentiation -- and do not respond to this approach.
Ongoing research is exploring alpha-emitting radioligands (such as 225Ac-PSMA), which deliver higher-energy radiation over shorter distances, potentially improving tumor kill while further reducing normal tissue exposure. Combinations with DNA-repair inhibitors are also under investigation to enhance cell-killing efficacy.
Androgen receptor pathway inhibitors (ARPIs) are next-generation hormonal therapies that work differently from traditional ADT. Rather than simply suppressing testosterone production, ARPIs directly block the AR protein, preventing it from receiving any signal and driving the cell toward growth.
Enzalutamide was among the first ARPIs approved for both nmCRPC (PROSPER trial) and mCRPC. It competes with androgens for AR binding, prevents the receptor from moving into the nucleus, and blocks it from activating cancer-promoting genes. Apalutamide (SPARTAN trial) demonstrated a metastasis-free survival of 40.5 months versus 16.2 months for placebo in nmCRPC patients.
Darolutamide has a distinct chemical structure that gives it a lower risk of crossing the blood-brain barrier, reducing neurological side effects. The ARAMIS trial showed benefit in nmCRPC, and the ARASENS trial demonstrated that combining darolutamide with docetaxel in mCRPC improved overall survival: 63% of patients in the combination arm were alive at 4 years versus 50% in the placebo arm.
Despite their effectiveness, ARPIs eventually fail in most patients due to acquired resistance -- primarily through the AR-V7 splice variant, which lacks the drug-binding domain entirely and cannot be blocked by any current ARPI. Identifying AR-V7-positive patients before ARPI therapy can spare them ineffective treatment and guide selection of alternative strategies.
Approximately 20-25% of metastatic CRPC patients carry mutations in DNA repair genes, most commonly BRCA1, BRCA2, and ATM. These mutations impair the cell's ability to fix double-strand DNA breaks through a process called homologous recombination. PARP inhibitors exploit this weakness by blocking a backup DNA repair pathway, causing catastrophic DNA damage specifically in repair-deficient cancer cells.
Olaparib was the first PARP inhibitor approved for mCRPC, based on the TOPARP-A and PROfound trials. PROfound demonstrated that olaparib significantly improved progression-free survival in patients with BRCA1/2 or ATM mutations who had progressed on prior ARPI therapy. This approval introduced biomarker-driven treatment selection as a formal part of prostate cancer care.
The combination of niraparib plus abiraterone (MAGNITUDE trial) showed approximately a 50% reduction in progression risk among BRCA-mutated mCRPC patients, supporting the principle that simultaneous AR and DNA-repair blockade is more effective than either alone. This reflected a broader trend toward combining mechanisms to delay resistance.
The combination of talazoparib plus enzalutamide (TALAPRO-2 trial) became the first approved PARP inhibitor plus ARPI combination in 2023 -- approved regardless of BRCA mutation status, not only for patients with DNA repair defects. This broader approval reflects emerging evidence that PARP inhibition may provide benefits beyond purely mutation-driven mechanisms.
Prostate cancer has historically been considered poorly responsive to immunotherapy because it tends to have low tumor mutational burden (TMB) and an immunosuppressive tumor microenvironment with few infiltrating immune cells. These features limit the effectiveness of the immune checkpoint inhibitors that transformed other cancer types.
Pembrolizumab (anti-PD-1) is approved for prostate cancer only in a narrow, biomarker-selected subset: patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, which represent approximately 3-5% of CRPC cases. For the broader population, checkpoint inhibitors alone have not shown meaningful clinical benefit.
The CONTACT-02 trial investigated atezolizumab plus cabozantinib (an anti-PD-L1 checkpoint inhibitor combined with a tyrosine kinase inhibitor that targets the immunosuppressive tumor microenvironment). Combinations like this aim to 'warm up' cold tumors by changing the microenvironment before adding immune checkpoint blockade.
Sipuleucel-T (Provenge), the only FDA-approved tumor vaccine for prostate cancer, works by stimulating the patient's own immune cells to target prostatic acid phosphatase (PAP). The IMPACT trial showed a 4.1-month overall survival benefit. However, its high cost, complex manufacturing, and lack of PSA response despite survival benefit have limited widespread adoption. PROSTVAC, a viral vector vaccine, failed to show benefit in its phase III trial.
Beyond the established treatment targets, researchers are investigating a range of novel molecular targets in CRPC. Heat shock proteins (HSPs), particularly HSP90 and HSP70, are molecular chaperones that stabilize the AR and other oncoproteins. HSF1, the transcription factor that drives HSP production, is being targeted by NXP800, which is currently in clinical trials for multiple solid tumors.
STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1) is highly overexpressed in prostate cancer and is being explored as a target for antibody-drug conjugates and CAR-T cell therapies. Glucocorticoid receptors (GR) can bypass AR blockade by taking over many of the same gene expression programs, contributing to ARPI resistance -- making GR antagonism a rational strategy in enzalutamide-resistant disease.
Estrogen receptors (ERs), particularly ER-beta, play complex roles in prostate cancer and can suppress AR activity. Selective estrogen receptor modulators (SERMs) and degraders (SERDs) are being evaluated as approaches to exploit this biology. Integrin-targeting strategies aim to disrupt cancer cell adhesion and invasion, while CBP/p300 inhibitors block transcriptional coactivators that cooperate with AR to drive gene expression.
Exosome-based therapies represent a preclinical frontier. Tumor-derived exosomes -- tiny vesicles released by cancer cells -- carry molecular signals that suppress immune responses and facilitate metastasis. Blocking exosome release or using engineered exosomes as drug delivery vehicles are both under investigation, though clinical translation remains distant.
The treatment landscape for CRPC has been fundamentally transformed over the past decade. What was once a disease with few options beyond chemotherapy now has multiple approved drug classes -- ARPIs, PARP inhibitors, radioligand therapy, and immunotherapy -- each targeting distinct molecular vulnerabilities and each requiring careful patient selection.
The key lesson from recent trial data is that treatment sequencing and biomarker testing are as important as the drugs themselves. Germline and somatic DNA repair gene testing (BRCA1/2, ATM) is now standard in mCRPC to guide PARP inhibitor eligibility. AR-V7 testing can identify patients who are unlikely to benefit from ARPIs. PSMA PET imaging guides radioligand therapy eligibility.
Combination approaches are becoming the dominant strategy. Rather than cycling through single agents sequentially, trials like TALAPRO-2 and ARASENS have demonstrated that simultaneous blockade of complementary pathways produces durable responses. The challenge is identifying which combinations work best for which molecular subtype of CRPC.
The ultimate goal is a fully personalized treatment algorithm: one that integrates genomic profiling, liquid biopsy results, imaging biomarkers, and treatment history to guide each individual patient to the therapy most likely to control their specific tumor while minimizing harm. This vision is increasingly achievable as molecular diagnostics and targeted therapies continue to advance together.